10:00 , Apr 18, 2019 |  BC Extra  |  Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

With a new management team at the helm, Talaris raised $100 million in a series A round Thursday and reported that FCR001 led to a 70% immune tolerance rate in a Phase II trial to...
03:38 , Jan 11, 2019 |  BC Innovations  |  Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
23:56 , Nov 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Colitis Mouse studies suggest exosome-like nanoparticles (ELNs) from the ginger plant or ginger-based nanovesicles loaded with ELN microRNA (miRNA) could help treat colitis. In a mouse model of colitis, ELNs derived from ginger or...
19:29 , Nov 7, 2018 |  BC Innovations  |  Translation in Brief

Expanding the reach of plant exosomes

A University of Louisville team has shown how plant-derived exosomes could mobilize the gut microbiome against colitis, broadening the range of potential indications for the technology beyond those the university already has in Phase I...
23:57 , Jul 26, 2018 |  BC Innovations  |  Targets & Mechanisms

PureTech plumbs the brain

PureTech Health plc is backing a new way of thinking about Alzheimer’s disease that positions it primarily as a problem of poor drainage, building on the recent discovery of lymphatic vessels in the brain by...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
07:00 , Oct 1, 2015 |  BC Innovations  |  Tools & Techniques

NCATS's extracellular revolution

Two years into its five-year run, a $117.5 million NIH-funded consortium established to look for biomarkers and therapies stemming from extracellular RNA (exRNA) research is now moving into its testing and validation phase, after completing...
07:00 , Apr 30, 2015 |  BC Innovations  |  Distillery Techniques

Therapeutics: Grapefruit-derived nanoparticles for delivering drugs to sites of inflammation

Drug delivery TECHNOLOGY: Nanoparticles Grapefruit-derived nanoparticles targeted to inflammation sites could help deliver drugs for cancer and other diseases involving inflammation. The nanoparticles consisted of exosome-like particles derived from grapefruit coated with membranes from activated...
08:00 , Nov 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Toll-like receptor 4 (TLR4); HPV antigens; survivin (BIRC5) Mouse studies suggest a combination of adjuvants could help improve the efficacy of cancer vaccines. The...
07:00 , Oct 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer IL-10 Mouse studies suggest orally available microparticles that deliver IL-10 could help suppress polyposis to prevent colorectal cancer. In a mouse model of...